Jyoti Malhotra, MD, MPH

Jyoti Malhotra, MD, MPH, is the interim division chief of Thoracic Medical Oncology at City of Hope, and an associate professor in the Department of Medical Oncology & Therapeutics and research director of Thoracic Medical Oncology at City of Hope Orange County.

Articles

Unmet Needs to Address in Advanced NSCLC

October 16th 2025

Julia Rotow, MD, and Jyoti Malhotra, MD, MPH, discuss unmet needs in advanced NSCLC.

Novel Biomarkers to Watch in Advanced NSCLC

October 16th 2025

Julia Rotow, MD, and Jyoti Malhotra, MD, MPH, discuss novel biomarkers under investigation in advanced NSCLC.

Exploring Sigvotatug Vedotin–Based Combinations in Advanced NSCLC

October 7th 2025

Julia Rotow, MD, and Jyoti Malhotra, MD, MPH, discuss the investigation of sigvotatug vedotin plus pembrolizumab in NSCLC.

Evaluation of Sigvotatug Vedotin Monotherapy in Previously Treated, Nonsquamous NSCLC

October 7th 2025

Julia Rotow, MD, and Jyoti Malhotra, MD, MPH, discuss the investigation of sigvotatug vedotin in nonsquamous NSCLC.

Treatment Approaches and Unmet Needs in Second-Line Advanced NSCLC

September 22nd 2025

Julia Rotow, MD, and Jyoti Malhotra, MD, MPH, discuss unmet needs in second-line non–small cell lung cancer.

Rationale for Evaluating IB6 as a Potential Therapeutic Target in NSCLC

September 22nd 2025

Julia Rotow, MD, and Jyoti Malhotra, MD, MPH, discuss the rationale for evaluating IB6 as a target in non–small cell lung cancer.

Dr Malhotra on Persisting Knowledge Gaps Surrounding the Use of ADCs in Lung Cancer

August 27th 2025

Jyoti Malhotra, MD, MPH, discusses current knowledge of ADC efficacy in patients with NSCLC and brain metastases.

Dr Malhotra on the Future of Sigvotatug Vedotin in NSCLC

August 7th 2025

Jyoti Malhotra, MD, MPH, discusses future research directions for sigvotatug vedotin in non–small cell lung cancer.

Dr. Malhotra on Challenges with Precision Medicine in Advanced Solid Tumors

November 23rd 2021

Jyoti Malhotra, MD, MPH, discusses challenges with precision medicine in advanced solid tumors.

Dr. Malhotra on the Rationale to Evaluate Racial Disparities in Lung Cancer Survivors

August 5th 2021

Jyoti Malhotra, MD, MPH, discusses the rationale to evaluate racial disparities in lung cancer survivors.

Dr. Malhotra on the Safety Profile of Plinabulin/Nivolumab/Ipilimumab in Relapsed SCLC

June 23rd 2021

Jyoti Malhotra, MD, MPH, discusses the safety profile of plinabulin in combination with nivolumab and ipilimumab in relapsed/refractory small cell lung cancer.

Dr. Malhotra on Pembrolizumab During Concurrent Chemoradiation in NSCLC

July 9th 2019

Jyoti Malhotra, MD, MPH, discusses a phase I multicenter trial of PD-1 blockade with pembrolizumab with concurrent chemoradiation in patients with locally advanced, unresectable non–small cell lung cancer.